<!DOCTYPE html>
<html lang="en-US"><head>
		<meta charset="UTF-8">
		<title>FR940627-0-00152</title>
	</head>
	<body>
		<main>
			<p><!-- PJG STAG 4700 -->  <!-- PJG ITAG l=11 g=1 f=1 --> In the NPRM, EPA proposed to require modeling or other  <!-- PJG 0012 frnewline --> analytic methods to evaluate potential exposures, expected  <!-- PJG 0012 frnewline --> atmospheric reactivity, and environmental partitioning of  <!-- PJG 0012 frnewline --> emission products. However, as discussed in Section III.C., this  <!-- PJG 0012 frnewline --> final rule does not require modeling analyses to be performed as  <!-- PJG 0012 frnewline --> routine requirements under Tier 1. Instead, quantitative  <!-- PJG 0012 frnewline --> modeling efforts will be required on a case-by-case basis as  <!-- PJG 0012 frnewline --> needed under Tier 3.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> Nevertheless, EPA believes that exposure data are still  <!-- PJG 0012 frnewline --> critical for the assessment of the potential risks associated  <!-- PJG 0012 frnewline --> with the emissions of F/FAs in question. For this purpose,  <!-- PJG 0012 frnewline --> today's rule requires manufacturers to provide a qualitative  <!-- PJG 0012 frnewline --> discussion of potential population exposures based on the  <!-- PJG 0012 frnewline --> production and use of the particular fuel or additive (or group  <!-- PJG 0012 frnewline --> of F/FAs) in question. This qualitative analysis must consider  <!-- PJG 0012 frnewline --> the actual and/or projected total annual production volumes and  <!-- PJG 0012 frnewline --> the market distribution patterns (e.g., percent of sales by state  <!-- PJG 0012 frnewline --> or region) of the particular product or group of products. Group  <!-- PJG 0012 frnewline --> submissions must assess the cumulative exposure resulting from  <!-- PJG 0012 frnewline --> all members of the group. A quantitative analysis is encouraged  <!-- PJG 0012 frnewline --> when appropriate data are available, including any existing  <!-- PJG 0012 frnewline --> modeling data, to support the exposure analysis. As discussed  <!-- PJG 0012 frnewline --> earlier, EPA retains the authority to require from manufacturers  <!-- PJG 0012 frnewline --> more exhaustive exposure analysis for particular products of  <!-- PJG 0012 frnewline --> concern under Tier 3 (including modeling), based on the EPA  <!-- PJG 0012 frnewline --> evaluation of Tier 1 and Tier 2 results or other available  <!-- PJG 0012 frnewline --> information.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=84 g=1 f=1 --> VIII. Tier 2 Requirements  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> In the NPRM, EPA proposed short-term (42-day) tests under  <!-- PJG 0012 frnewline --> Tier 2 for the evaluation of six health effects endpoints:  <!-- PJG 0012 frnewline --> carcinogenicity, mutagenicity, teratogenicity, reproductive  <!-- PJG 0012 frnewline --> toxicity, neurotoxicity, and pulmonary toxicity. EPA examined  <!-- PJG 0012 frnewline --> the proposed Tier 2 program and found that similar requirements  <!-- PJG 0012 frnewline --> among the various proposed tests (in regard to animal subjects,  <!-- PJG 0012 frnewline --> exposure scenarios, and general technical principles) provided  <!-- PJG 0012 frnewline --> the opportunity to combine several endpoint tests within the same  <!-- PJG 0012 frnewline --> exposure protocol. In view of this, EPA has modified the Tier 2  <!-- PJG 0012 frnewline --> testing program to allow for concurrent test performance in a  <!-- PJG 0012 frnewline --> more cost-effective manner.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> The revised Tier 2 testing program enhances efficiency and  <!-- PJG 0012 frnewline --> feasibility, while providing better health effects information.  <!-- PJG 0012 frnewline --> In fact, the design of the Tier 2 testing program makes best use  <!-- PJG 0012 frnewline --> of animals (minimum number of animals used), laboratory capacity,  <!-- PJG 0012 frnewline --> and financial resources. The basic Tier 2 testing framework of  <!-- PJG 0012 frnewline --> this final rule consists of a 90-day subchronic inhalation study  <!-- PJG 0012 frnewline --> to examine general systemic and organ toxicity (including  <!-- PJG 0012 frnewline --> pulmonary effects), with the addition of ancillary tests that  <!-- PJG 0012 frnewline --> allow the assessment of several specific health effect endpoints  <!-- PJG 0012 frnewline --> (carcinogenicity, mutagenicity, teratogenicity, reproductive  <!-- PJG 0012 frnewline --> toxicity, and neurotoxicity) within the same exposure schedule.  <!-- PJG 0012 frnewline --> A fertility assessment is coordinated with the 90-day study to  <!-- PJG 0012 frnewline --> examine reproductive and teratogenic effects.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> Brief descriptions of test guidelines for the evaluation of  <!-- PJG 0012 frnewline --> each health effect endpoint are provided in the sections below.  <!-- PJG 0012 frnewline --> Most of these testing guidelines are modified versions of  <!-- PJG 0012 frnewline --> guidelines previously published under TSCA (40 CFR part 798,  <!-- PJG 0012 frnewline --> revised as of July 1, 1992) and/or the test guidelines which  <!-- PJG 0012 frnewline --> accompanied the NPRM. Detailed protocols for the Tier 2 testing  <!-- PJG 0012 frnewline --> program are included in &sect;79.62&hyph;&sect;79.68 of the accompanying  <!-- PJG 0012 frnewline --> regulations. Figure 4 shows a diagram of the suggested timing  <!-- PJG 0012 frnewline --> and organization of the Tier 2 studies within the general 90-day  <!-- PJG 0012 frnewline --> subchronic exposure schedule. <!-- PJG /ITAG -->  <!-- PJG QTAG 03 --> <!-- PJG /QTAG -->   <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <BILLING> <!-- PJG ITAG l=68 g=1 f=1 --> BILLING CODE 6560&hyph;50&hyph;P <!-- PJG /ITAG --> </BILLING>  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0101 clearpage -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /STAG -->  <!-- PJG STAG 4725 -->  <IMPORT>  <!-- PJG importformat s,d585 -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=95 g=1 f=1 --> E:GRAPHICSER27JN94.002 <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG QTAG 03 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  </IMPORT>  <!-- PJG /STAG -->  <!-- PJG STAG 4700 -->  <BILLING> <!-- PJG ITAG l=68 g=1 f=1 --> BILLING CODE 6560&hyph;50&hyph;C <!-- PJG /ITAG --> </BILLING>  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0101 clearpage -->  <!-- PJG 0012 frnewline -->  <!-- PJG /STAG --></p>
		</main>
</body></html>
            